[可切除非小细胞肺癌新辅助免疫疗法的进展]。

Q4 Medicine

中国肺癌杂志 Pub Date : 2024-02-20 DOI:10.3779/j.issn.1009-3419.2024.102.06

Chang Qi, Panwen Tian, Weimin Li

{"title":"[可切除非小细胞肺癌新辅助免疫疗法的进展]。","authors":"Chang Qi, Panwen Tian, Weimin Li","doi":"10.3779/j.issn.1009-3419.2024.102.06","DOIUrl":null,"url":null,"abstract":"In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application.\u2029.","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 2","pages":"138-146"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918244/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].\",\"authors\":\"Chang Qi, Panwen Tian, Weimin Li\",\"doi\":\"10.3779/j.issn.1009-3419.2024.102.06\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application.\\u2029.\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"27 2\",\"pages\":\"138-146\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918244/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2024.102.06\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2024.102.06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

近年来，通过使用免疫检查点抑制剂（ICIs）改善晚期非小细胞肺癌（NSCLC）患者的预后已成为共识。大量临床研究也证明了免疫疗法对可切除的 NSCLC 患者的重要价值。然而，在新辅助治疗中，围绕免疫联合策略的探索、治疗相关副作用、预后生物标志物以及其他问题仍存在争议。因此，本文全面概述了可切除NSCLC新辅助免疫疗法的最新进展，激发了人们的新视角，并深入探讨了其在临床应用中的优点和挑战。.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

In recent years, there has been a consensus regarding the enhancement of prognosis in patients with advanced non-small cell lung cancer (NSCLC) through the utilization of immune checkpoint inhibitors (ICIs). Numerous clinical studies have also demonstrated the substantial value of immunotherapy for resectable NSCLC patients. Nevertheless, there remain controversies surrounding the exploration of immune combination strategies, treatment-related side effects, prognostic biomarkers, as well as other issues in the neoadjuvant therapy setting. Consequently, this article presents a comprehensive overview of the recent advancements in neoadjuvant immunotherapy for resectable NSCLC, stimulating fresh perspectives and delving into its merits and challenges in clinical application. .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

5131

审稿时长

14 weeks

期刊介绍： Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.